- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04320693
Expanded Access for IMMU-132
August 12, 2021 updated by: Gilead Sciences
This is an expanded access program (EAP) for eligible participants designed to provide access to IMMU-132.
Study Overview
Status
Approved for marketing
Conditions
Intervention / Treatment
Study Type
Expanded Access
Expanded Access Type
- Individual Patients
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Description
Inclusion Criteria:
-
Exclusion Criteria:
-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
March 19, 2020
First Submitted That Met QC Criteria
March 19, 2020
First Posted (Actual)
March 25, 2020
Study Record Updates
Last Update Posted (Actual)
August 19, 2021
Last Update Submitted That Met QC Criteria
August 12, 2021
Last Verified
April 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IMMU-132
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Triple-Negative Breast Carcinoma
-
University of California, San FranciscoJohns Hopkins University; Gilead Sciences; Translational Breast Cancer Research...RecruitingMetastatic Breast Cancer | Metastatic Triple-Negative Breast Carcinoma | HER2-negative Breast Cancer | HER2 Negative Breast Carcinoma | Metastatic Triple Negative Breast Cancers | HR+ HER2 Breast CancerUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingBreast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Breast Cancer Stage IV | Locally Advanced Breast Cancer | Metastatic Triple-Negative Breast Carcinoma | Locally Advanced Triple-Negative Breast CarcinomaUnited States
-
Karolinska University HospitalTerminatedMetastatic Triple-Negative Breast CarcinomaSweden
-
Fundacio Clinic BarcelonaSOLTI Breast Cancer Research GroupNot yet recruitingMetastatic Triple-Negative Breast CarcinomaSpain
-
OncoPep, Inc.Not yet recruitingMetastatic Triple-Negative Breast Carcinoma
-
National Cancer Institute (NCI)WithdrawnAnatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Invasive Breast Carcinoma | Metastatic Triple-Negative Breast Carcinoma | Metastatic HER2-Negative Breast Carcinoma | Unresectable Triple-Negative Breast Carcinoma | Locally Advanced Triple-Negative Breast Carcinoma and other conditionsUnited States
-
National Cancer Institute (NCI)RecruitingAnatomic Stage IV Breast Cancer AJCC v8 | Invasive Breast Carcinoma | Metastatic Triple-Negative Breast CarcinomaUnited States
-
Emory UniversityNational Cancer Institute (NCI)Not yet recruitingAnatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma | Unresectable Triple-Negative Breast Carcinoma | Refractory Triple-Negative Breast CarcinomaUnited States
-
National Cancer Institute (NCI)RecruitingAnatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma | Unresectable Triple-Negative Breast Carcinoma | Locally Advanced Triple-Negative Breast CarcinomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)TerminatedAnatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma | Unresectable Triple-Negative Breast CarcinomaUnited States
Clinical Trials on IMMU-132
-
Peking University Cancer Hospital & InstituteRecruitingBreast Cancer | Brain Metastases From Breast Cancer | Trop2China
-
Gilead SciencesCompletedCervical Cancer | Urinary Bladder Neoplasms | Small Cell Lung Cancer | Hepatocellular Carcinoma | Pancreatic Cancer | Esophageal Cancer | Ovarian Epithelial Cancer | Glioblastoma Multiforme | Gastric Adenocarcinoma | Triple Negative Breast Cancer | Endometrial Cancer | Non-small Cell Lung Cancer | Renal Cell Cancer and other conditionsUnited States
-
Gilead SciencesWithdrawnTriple-negative Breast Cancer
-
Gilead SciencesRecruitingLiver Failure | Advanced or Metastatic Solid TumorFrance, Spain, United States, Italy
-
Gilead SciencesParexel; IQVIA RDS (Shanghai) Co., Ltd.; Medidata Solutions; Q Squared Solutions...Active, not recruitingMetastatic Triple-negative Breast CancerChina
-
University of Wisconsin, MadisonNational Cancer Institute (NCI); Gilead SciencesActive, not recruiting
-
Yale UniversityGilead SciencesActive, not recruitingOvarian CarcinomaUnited States
-
Gilead SciencesActive, not recruiting
-
Yale UniversityGilead SciencesActive, not recruitingEndometrial CarcinomaUnited States
-
Gilead SciencesRecruitingAdvanced Solid TumorsUnited States, Israel